Doubling Down on Mutant RAS Can MEK or Break Leukemia.
Cell
Authors | |
Keywords | |
Abstract | Targeting of the RAS pathway has long been a critical therapeutic challenge in oncology. Burgess et al. examine how the relative expression of mutant and wild-type KRAS modulates clonal fitness and sensitivity to MEK inhibitors in a model of Kras(G12D) mutant acute myeloid leukemia and propose its use as a predictive biomarker. |
Year of Publication | 2017
|
Journal | Cell
|
Volume | 168
|
Issue | 5
|
Pages | 749-750
|
Date Published | 2017 02 23
|
ISSN | 1097-4172
|
DOI | 10.1016/j.cell.2017.02.013
|
PubMed ID | 28235190
|
Links |